Rohan R. Narkhede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rohan R. Narkhede has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Rameshwar S. Cheke
Department of Pharmaceutical Sciences and Technology Institute of Chemical Technology Mumbai India
2 shared publications - Sachin D. Shinde
Department of Pharmacology, Shri R. D. Bhakt College of Pharmacy
2 shared publications - Vaishali M. Patil
Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, India
2 shared publications - Aadesh Kumar
Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, U.P. 250005, India
1 shared publication - Ashwini V. Pise
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Lucknow, 226002, India
1 shared publication - Nidhi Dhama
Faculty of Pharmacy, Swami Vivekanand Subharti University, Meerut, U.P. 250005, India
1 shared publication
Latest Publications
- Open Access
- 28 April 2023
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 35 (5) , 1135-1145
Synthesis, Characterization, Docking Studies and Antiepileptic Activity of Novel Piracetam Derivatives
Piracetam is a nootropic drug that has been used in clinical trials for decades, but is still a mystery due to a lack of understanding of its mechanism of action. In this research, sixteen novel piracetam derivatives were synthesized in three steps and characterized by IR, NMR and mass spectroscopic techniques. Based on the docking studies, two derivatives were identified as more active based on the drug receptor interactions studies and were further subjected to animal studies for the evaluation of the activity. Compounds 6 and 10 had shown a strong anticonvulsant activity based on the molecular docking studies. It was hypothesized from the synthesized analogues that the non-substitution with thio moiety at has a major effect on reducing the contagiousness of seizure discharge and increasing the seizure threshold.
- 28 April 2023
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 35 (5) , 1135-1145
Open AccessSynthesis, Characterization, Docking Studies and Antiepileptic Activity of Novel Piracetam Derivatives
Piracetam is a nootropic drug that has been used in clinical trials for decades, but is still a mystery due to a lack of understanding of its mechanism of action. In this research, sixteen novel piracetam derivatives were synthesized in three steps and characterized by IR, NMR and mass spectroscopic techniques. Based on the docking studies, two derivatives were identified as more active based on the drug receptor interactions studies and were further subjected to animal studies for the evaluation of the activity. Compounds 6 and 10 had shown a strong anticonvulsant activity based on the molecular docking studies. It was hypothesized from the synthesized analogues that the non-substitution with thio moiety at has a major effect on reducing the contagiousness of seizure discharge and increasing the seizure threshold.
- 1 August 2021
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
- Vol. 19 (4) , 3-14
Understanding the Dynamics of COVID-19 Outbreak: Structure, Diagnosis, Prevention and Treatment
Currently, mankind is fighting against an invisible enemy. The novel Coronavirus disease (COVID-19) has been spreading at a rapid rate across the world, which made the World Health Organization (WHO) to declare it as pandemic disease. COVID-19 is an acute respiratory tract infection that was first reported in December 2019, initially presented as pneumonia of unknown etiology in a group of patients in Wuhan, a city in the Hubei Province of China. Sometimes, animals infected with coronavirus infect humans and spread further via human-to-human transmission similar to the case of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome-related coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as 2019-nCoV (COVID-19). SARS-- CoV-2 is an extremely pathogenic virus and is crushing the well-equipped health systems of developed countries. According to the WHO situation report updated on October 25, 2020 over 42 million cases and 1.1 million deaths have been reported globally. Since the figure of cases continues to increase, these viruses create a threat to global public health. This review summarizes an overview of the study of the novel coronavirus, including origin, epidemiology, etiology, targets for viral entry, and describes the clinical manifestation, diagnosis, and therapeutics used in clinical settings. Furthermore, our review focuses on the most up-to-date clinical information for the effective management, prevention, and counseling to control COVID-19 worldwide.
- 1 August 2021
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
- Vol. 19 (4) , 3-14
Understanding the Dynamics of COVID-19 Outbreak: Structure, Diagnosis, Prevention and Treatment
Currently, mankind is fighting against an invisible enemy. The novel Coronavirus disease (COVID-19) has been spreading at a rapid rate across the world, which made the World Health Organization (WHO) to declare it as pandemic disease. COVID-19 is an acute respiratory tract infection that was first reported in December 2019, initially presented as pneumonia of unknown etiology in a group of patients in Wuhan, a city in the Hubei Province of China. Sometimes, animals infected with coronavirus infect humans and spread further via human-to-human transmission similar to the case of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome-related coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as 2019-nCoV (COVID-19). SARS-- CoV-2 is an extremely pathogenic virus and is crushing the well-equipped health systems of developed countries. According to the WHO situation report updated on October 25, 2020 over 42 million cases and 1.1 million deaths have been reported globally. Since the figure of cases continues to increase, these viruses create a threat to global public health. This review summarizes an overview of the study of the novel coronavirus, including origin, epidemiology, etiology, targets for viral entry, and describes the clinical manifestation, diagnosis, and therapeutics used in clinical settings. Furthermore, our review focuses on the most up-to-date clinical information for the effective management, prevention, and counseling to control COVID-19 worldwide.
- Open Access
- 17 June 2020
- Published by Springer Nature in Natural Products and Bioprospecting
- Vol. 10 (5) , 297-306
Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
SARS-CoV-2 (2019-nCoV) emerged in 2019 and proliferated rapidly across the globe. Scientists are attempting to investigate antivirals specific to COVID-19 treatment. The 2019-nCoV and SARS-CoV utilize the same receptor of the host which is COVID-19 of the main protease (Mpro).COVID-19 caused by SARS-CoV-2 is burdensome to overcome by presently acquired antiviral candidates. So the objective and purpose of this work was to investigate the plants with reported potential antiviral activity. With the aid of in silico techniques such as molecular docking and druggability studies, we have proposed several natural active compounds including glycyrrhizin, bicylogermecrene, tryptanthrine, β-sitosterol, indirubin, indican, indigo, hesperetin, crysophanic acid, rhein, berberine and β-caryophyllene which can be encountered as potential herbal candidate exhibiting anti-viral activity against SARS-CoV-2. Promising docking outcomes have been executed which evidenced the worthy of these selected herbal remedies for future drug development to combat coronavirus disease.Graphic
- 17 June 2020
- Published by Springer Nature in Natural Products and Bioprospecting
- Vol. 10 (5) , 297-306
Open AccessRecognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
SARS-CoV-2 (2019-nCoV) emerged in 2019 and proliferated rapidly across the globe. Scientists are attempting to investigate antivirals specific to COVID-19 treatment. The 2019-nCoV and SARS-CoV utilize the same receptor of the host which is COVID-19 of the main protease (Mpro).COVID-19 caused by SARS-CoV-2 is burdensome to overcome by presently acquired antiviral candidates. So the objective and purpose of this work was to investigate the plants with reported potential antiviral activity. With the aid of in silico techniques such as molecular docking and druggability studies, we have proposed several natural active compounds including glycyrrhizin, bicylogermecrene, tryptanthrine, β-sitosterol, indirubin, indican, indigo, hesperetin, crysophanic acid, rhein, berberine and β-caryophyllene which can be encountered as potential herbal candidate exhibiting anti-viral activity against SARS-CoV-2. Promising docking outcomes have been executed which evidenced the worthy of these selected herbal remedies for future drug development to combat coronavirus disease.Graphic